INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Remains hospitalized after birth (has never been   │ Remains hospitalized after birth (has never been   │     100 │
│ discharged home)                                   │ discharged home)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treating clinician deems infant eligible to        │ Treating clinician deems infant eligible to        │     100 │
│ receive 2-month vaccines                           │ receive 2-month vaccines                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ English- or Spanish-speaking parent(s)/legally     │ English- or Spanish-speaking parent(s)/legally     │     100 │
│ authorized representative(s) (LAR(s))              │ authorized representative(s) (LAR(s))              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Not planned for discharge within 60 hours of study │ Not planned for discharge within 60 hours of study │     100 │
│ entry                                              │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The parent/guardian must be willing and capable of │ The parent/guardian must be willing and capable of │     100 │
│ providing permission for their child to            │ providing permission for their child to            │         │
│ participate through the written informed consent   │ participate through the written informed consent   │         │
│ process                                            │ process                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Receipt of DTaP, IPV, PCV13, or Hib prior to       │ Receipt of DTaP, IPV, PCV13, or Hib prior to       │     100 │
│ enrollment. Previous administration of the first   │ enrollment. Previous administration of the first   │         │
│ dose of HBV is permitted                           │ dose of HBV is permitted                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticipated receipt of any vaccine other than      │ Anticipated receipt of any vaccine other than      │     100 │
│ DTaP, IPV, HBV, PCV13, or Hib during the first 60  │ DTaP, IPV, HBV, PCV13, or Hib during the first 60  │         │
│ hours after randomization                          │ hours after randomization                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of a severe allergic reaction (e.g.        │ History of a severe allergic reaction (e.g.        │     100 │
│ anaphylaxis) to a previous dose of any hepatitis B │ anaphylaxis) to a previous dose of any hepatitis B │         │
│ vaccine                                            │ vaccine                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of a severe allergic reaction (e.g.        │ History of a severe allergic reaction (e.g.        │     100 │
│ anaphylaxis) to any component of the vaccines used │ anaphylaxis) to any component of the vaccines used │         │
│ in the study including neomycin, yeast and         │ in the study including neomycin, yeast and         │         │
│ polymyxin B                                        │ polymyxin B                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of latex allergy                           │ History of latex allergy                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of unstable progressive neurologic         │ History of unstable progressive neurologic         │     100 │
│ disorder of unknown cause                          │ disorder of unknown cause                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known cause of apnea other than apnea of           │ Known cause of apnea other than apnea of           │     100 │
│ prematurity                                        │ prematurity                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cyanotic heart disease (congenital or acquired)    │ Cyanotic heart disease (congenital or acquired)    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Child or parent/LAR is an immediate relative of    │ Child or parent/LAR is an immediate relative of    │     100 │
│ study staff or an employee who is supervised by    │ study staff or an employee who is supervised by    │         │
│ study staff                                        │ study staff                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that would, in the opinion of the    │ Any condition that would, in the opinion of the    │     100 │
│ site investigator, place the participant at an     │ site investigator, place the participant at an     │         │
│ unacceptable risk of injury or render the          │ unacceptable risk of injury or render the          │         │
│ participant unable to meet the requirements of the │ participant unable to meet the requirements of the │         │
│ protocol                                           │ protocol                                           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 6 Weeks                   │ Known cause of apnea other than apnea of           │      36 │
│                                                    │ prematurity                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active infection being treated with systemic       │ Treating clinician deems infant eligible to        │      40 │
│ antimicrobials\*                                   │ receive 2-month vaccines                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Requiring mechanical ventilation or support with   │ Treating clinician deems infant eligible to        │      41 │
│ nasal intermittent positive pressure ventilation   │ receive 2-month vaccines                           │         │
│ (NIPPV)\*                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active known respiratory infection within 48 hours │ Not planned for discharge within 60 hours of study │      47 │
│ prior to randomization\*                           │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fever ≥38°C within 48 hours prior to               │ =6 weeks postnatal age at randomization            │      48 │
│ randomization\*                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major invasive medical or surgical procedure       │ Anticipated receipt of any vaccine other than      │      48 │
│ (including circumcision) within 48 hours prior to  │ DTaP, IPV, HBV, PCV13, or Hib during the first 60  │         │
│ randomization or anticipated to have major         │ hours after randomization                          │         │
│ invasive medical or surgical procedure during the  │                                                    │         │
│ first 60 hours after randomization\*               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \*This may result in a temporary delay of          │ =6 weeks postnatal age at randomization            │      53 │
│ randomization                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \*This may result in a temporary delay of          │ =6 weeks postnatal age at randomization            │      53 │
│ randomization                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \*This may result in a temporary delay of          │ =6 weeks postnatal age at randomization            │      53 │
│ randomization                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \*This may result in a temporary delay of          │ =6 weeks postnatal age at randomization            │      53 │
│ randomization                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \*This may result in a temporary delay of          │ =6 weeks postnatal age at randomization            │      53 │
│ randomization                                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≥6 weeks and 0 days and ≤12 weeks and 0 days       │ =6 weeks postnatal age at randomization            │      67 │
│ postnatal age at randomization                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \<33 and 0 days weeks gestational age at birth     │ =32 weeks gestational age at birth                 │      80 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════╤═════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                           │   Score │
╞════════════════════════════════════════════════╪═════════════════════════════════════════╪═════════╡
│ ≥6 weeks and 0 days and ≤12 weeks and 0 days   │ =6 weeks postnatal age at randomization │      67 │
│ postnatal age at randomization                 │                                         │         │
├────────────────────────────────────────────────┼─────────────────────────────────────────┼─────────┤
│ \<33 and 0 days weeks gestational age at birth │ =32 weeks gestational age at birth      │      80 │
╘════════════════════════════════════════════════╧═════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 77
Average Levenshtein Ratio of individual lines: 77.3
OverAll Ratio: 77.15
